These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 19251449)
1. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Karaca M; Magnan C; Kargar C Diabetes Metab; 2009 Apr; 35(2):77-84. PubMed ID: 19251449 [TBL] [Abstract][Full Text] [Related]
2. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Campbell RK J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360 [TBL] [Abstract][Full Text] [Related]
3. Beta-cell function and mass in type 2 diabetes. Larsen MO Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971 [TBL] [Abstract][Full Text] [Related]
4. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences. Lupi R; Del Prato S Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587 [TBL] [Abstract][Full Text] [Related]
5. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. Knop FK; Holst JJ; Vilsbøll T IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596 [TBL] [Abstract][Full Text] [Related]
6. Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions. Flatt PR; Green BD Biochem Soc Trans; 2006 Nov; 34(Pt 5):774-8. PubMed ID: 17052195 [TBL] [Abstract][Full Text] [Related]
7. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Ranganath LR J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745 [TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes-a matter of beta-cell life and death? Rhodes CJ Science; 2005 Jan; 307(5708):380-4. PubMed ID: 15662003 [TBL] [Abstract][Full Text] [Related]
9. From cradle to grave: pancreatic beta-cell mass and glucagon-like peptide-1. Wong VS; Brubaker PL Minerva Endocrinol; 2006 Jun; 31(2):107-24. PubMed ID: 16682935 [TBL] [Abstract][Full Text] [Related]
10. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. DeFronzo RA Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731 [TBL] [Abstract][Full Text] [Related]
11. Protection of pancreatic beta-cells: is it feasible? Bonora E Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375 [TBL] [Abstract][Full Text] [Related]
12. Beta cells in type 2 diabetes - a crucial contribution to pathogenesis. Maedler K Diabetes Obes Metab; 2008 May; 10(5):408-20. PubMed ID: 17451426 [TBL] [Abstract][Full Text] [Related]
14. Anatomical versus functional beta-cell mass in experimental diabetes. Kargar C; Ktorza A Diabetes Obes Metab; 2008 Nov; 10 Suppl 4():43-53. PubMed ID: 18834432 [TBL] [Abstract][Full Text] [Related]
15. [Effects of incretins on the regulation of beta-cell mass, proliferation and survival]. Kawamori D; Kaneto H Nihon Rinsho; 2011 May; 69(5):821-5. PubMed ID: 21595265 [TBL] [Abstract][Full Text] [Related]
16. Modulation of cyclic nucleotides and cyclic nucleotide phosphodiesterases in pancreatic islet beta-cells and intestinal L-cells as targets for treating diabetes mellitus. Furman B; Pyne N Curr Opin Investig Drugs; 2006 Oct; 7(10):898-905. PubMed ID: 17086934 [TBL] [Abstract][Full Text] [Related]
18. Awareness of pathophysiological concepts of type 2 diabetes: a survey in 847 physicians. Busse FP; Denti V; Stumvoll M Diabetes Res Clin Pract; 2007 Jun; 76(3):445-8. PubMed ID: 17321630 [TBL] [Abstract][Full Text] [Related]
19. Incretin based therapies for type 2 diabetes mellitus. Ghosh S; Collier A; Elhadd T; Malik I J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649 [TBL] [Abstract][Full Text] [Related]
20. Islet cell function: alpha and beta cells--partners towards normoglycaemia. Göke B Int J Clin Pract Suppl; 2008 Mar; (159):2-7. PubMed ID: 18269435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]